Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Primary, pathologically confirmed glioblastoma, and complete molecular biological marker tests (MGMT, 1p/19q, IDH, TERT, BRAF, p53, EGFR);~2. 2 \~ 6 weeks after operation; the surgical incision healed well;~3. Presence of lesions evaluable according to Rano criteria;~4. Aged 18-70 years;~5. Karnofsky performance status (KPS) ≥ 60;~6. The dose of corticosteroid therapy was stable or gradually reduced in the past 5 days;~7. No previous radiotherapy, chemotherapy, immunotherapy, or biologic therapy;~8. Serum hemoglobin ≥ 100 g/L, platelet count ≥ 80 × 109/L, neutrophil count ≥ 1.5 × 109/L;~9. Serum creatinine ≤ 1.25 × ULN or creatinine clearance ≥ 60 mL/min;~10. Serum bilirubin ≤ 1.5 × ULN, AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN, alkaline phosphatase ≤ 5 × ULN;~11. Normal coagulation function (PT prolongation does not exceed 3s, APTT prolongation does not exceed 10s);~12. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and be willing to use an appropriate method of contraception during the trial and 8 days after administration of the trial drug. Males must agree to use an appropriate method of contraception or be surgically sterile during the trial and after 8 weeks of trial drug administration;~13. Patient is sufficiently compliant with study and follow-up procedures;~14. Patients signed a formal informed consent form to indicate that they understood that the study was in accordance with hospital policy and ethical requirements.~Exclusion Criteria:~1. Secondary glioblastoma;~2. Patients with any other malignant tumor before or now, except skin non-melanotic carcinoma or cervical carcinoma in situ;~3. Any other diseases or conditions are contraindications to chemoradiotherapy (such as active phase of infection, within 6 months after cerebral myocardial infarction, symptomatic heart disease including unstable angina pectoris, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy);~4. Pregnant or lactating women;~5. Women and men who are likely to become pregnant but are unwilling to take appropriate contraceptive measures;~6. Evidence of hereditary bleeding constitution or coagulation disorders;~7. Patients requiring anticoagulant therapy due to other diseases;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- single-arm (Type: EXPERIMENTAL): single-arm Drug: Anlotinib Drug: Temozolomide Radiotherapy:Radiotherapy was initiated 4 to 6 weeks postoperatively at a dose of 1.8-2.0 Grays (Gy) per fraction for 5 days per week for 6 weeks with a total dose of 54-60 Gy.

Based on this trial design, predict the completion outcome and termination type (if applicable).